News | February 1, 1999

Glaxo Wellcome Expands PowderJect Collaboration

Having received an exclusive worldwide right to use PowderJect technology to commercialize a prophylactic DNA vaccine for hepatitis B last March, Glaxo Wellcome has exercised its option on one of four additional DNA vaccine products under its collaborative agreement with PowderJect Vaccines Inc.

In addition, Glaxo Wellcome has taken out a license to develop one of the seven vaccines over which it already held an option. Neither of the options is being specifically identified at this stage. The new agreement has generated fees paid to PowderJect of $1.5 million.

Under the existing alliance, Glaxo Wellcome had options to develop and commercialize the following DNA vaccine products using PowderJect technology:

  • Hepatitis B
  • Therapeutic vaccine
  • HIV therapeutic vaccine
  • Two therapeutic vaccines for undisclosed infectious diseases
  • Cancer vaccines using two undisclosed antigens
  • Four additional vaccine products to be selected by Glaxo Wellcome at a later date.

For more information: PowderJect Pharmaceuticals PLC, 4 Robert Robinson Ave., The Oxford Science Park, Oxford, OX4 4GA, England. Telephone: +44 (0)1865 782800. Fax: +44 (0)1865 782801.